HyperClear: 良性前列腺增生的雷射解決方案
先進的雷射系統,專為精確治療良性前列腺脹大 (BPH) 而設計,可有效去除組織、改善尿流,並縮短停工時間,以提升病患的療效。
HyperClear represents an innovative laser therapy system designed to effectively remove surplus prostatic tissue in benign prostatic hyperplasia (BPH). Leveraging the LIFE (Laser-Induced Fiber Enucleation) method, HyperClear applies precise laser energy via a flexible fiber placed transurethrally to the obstructive zone, ablating the excess prostate tissue responsible for lower urinary tract symptoms (LUTS). This approach may be performed outpatient—often with local anesthesia—enhancing patient comfort while maintaining efficacy and safety.
High-Precision Laser Fiber
- Optimized Energy Delivery: The laser fiber is advanced through the urethra to the blocked area, targeting surplus prostate tissue while minimizing collateral damage.
- LIFE Method: Focused on selective tissue vaporization or enucleation, ensuring clean resection planes and predictable tissue removal.
Outpatient Feasibility
- Local Anesthesia: Allows many patients to undergo the procedure without the risks or recovery times associated with general anesthesia.
- Rapid Recovery: Less invasive than conventional transurethral resections, potentially reducing hospital stays and improving patient throughput.
Real-Time Visualization
- Precise Tissue Identification: Endoscopic imaging guides the laser fiber to the obstructive tissue, ensuring thorough clearance of the prostatic urethra.
- Controlled Ablation: The surgeon can finely tune laser energy to match the tissue’s vascularity and density, limiting the risk of deep thermal damage.
Efficient & Gentle Tissue Removal
- Targeted Laser Ablation: Precisely removes hyperplastic prostate segments that hinder urine flow, preserving healthy tissue zones.
- Hemostatic Effect: Laser energy also cauterizes small vessels during tissue vaporization, reducing intraoperative bleeding.
臨床優勢與應用
Benign Prostatic Hyperplasia (BPH)
- Symptomatic Relief: Alleviates classic LUTS such as frequent urination, weak urine stream, and prolonged emptying times.
- Patient Selection: Suited for patients with moderate-to-severe BPH who seek a less invasive alternative to standard TURP or open prostatectomy.
Minimal Invasiveness
- Outpatient Possibility: Potentially performed under local anesthesia, minimizing hospitalization and facilitating early mobilization.
- Lower Bleeding Risk: Laser-based enucleation or vaporization significantly reduces hemorrhage compared to mechanical resection methods.
強化病患體驗
- Shorter Convalescence: Many patients resume daily activities sooner, with less postoperative discomfort or catheterization durations.
- Reduced Need for General Anesthesia: Local or spinal anesthesia lessens systemic risks, beneficial for older or comorbid patients.
Technical Specifications
| 規格 | 細節 / 價值 |
| 產品名稱 | CytroFIX® Superior Clavicula Plates |
| 材質 | High-Purity Titanium Alloy (e.g., Ti-6Al-4V ELI) |
| Plate Profile | Low-profile, contoured for superior clavicle placement |
| Locking Mechanism | Locking or non-locking titanium screws; optional variable-angle locking |
| Screw Diameter | 2.7 mm or 3.5 mm (titanium cortical screws, depending on hole specification) |
| Plate Thickness | ~2.0–2.5 mm (minimized profile) |
| Hole Array | Multiple holes for bridging, compression, or combined fixation patterns |
| 放射能力 | Titanium visible on fluoroscopy (optional etched markers) |
| 無菌 | Provided non-sterile (autoclavable) or sterile, single use or reusable instrumentation (verify product line) |
| 保質期 | Indefinite if stored properly; reusable within recommended inspection cycles |
| 臨床適應症 | Midshaft/lateral clavicle fractures requiring superior plating, osteotomies, nonunion correction |
| Regulatory Compliance | Conforms to ISO 13485, CE/FDA (region-specific), meets orthopedic implant standards |
Size & Ordering Matrix
| Plate Length (mm) | Hole Count | Curvature | Compatible Screw | 產品編號 | 注意事項 |
| 60 | 4 | Mild Superior Bend | 2.7 mm Locking/Non-Locking | CFX-SCL-60-4-27-Ti | Shorter plate for smaller fractures in lateral or mid-shaft |
| 70 | 5 | Mild Superior Bend | 2.7 mm Locking/Non-Locking | CFX-SCL-70-5-27-Ti | Extended coverage for mild to moderate fractures |
| 80 | 5 | Moderate Superior Bend | 2.7 or 3.5 mm Locking | CFX-SCL-80-5-MX-Ti | Bridges midshaft fractures with variable-angle options |
| 90 | 6 | Moderate Superior Bend | 3.5 mm Locking/Non-Locking | CFX-SCL-90-6-35-Ti | For larger or multi-fragment fractures requiring robust support |
| 100 | 7 | Enhanced Superior Contour | 3.5 mm Locking/Non-Locking | CFX-SCL-100-7-35-Ti | Accommodates more complex or extended fracture lines |
| 110 | 8 | Enhanced Superior Contour | 3.5 mm Locking/Non-Locking | CFX-SCL-110-8-35-Ti | Longest plate design for challenging multi-segment fractures |
相關商品
-

GlideAccess 輸尿管通路鞘管
查看內容此輸尿管通路鞘管專為流暢、有效率的導引而設計,可提供更佳的尿路通路,減少創傷,並方便泌尿系統手術中器械的通過。
-

整合式關節鏡幫浦
查看內容的 整合式關節鏡幫浦 是一個 保險, 可靠以及 易於使用 流體管理解決方案 連續, 無脈衝 控制 關節內沖洗 和 膨脹壓力 自始至終 每 關節鏡手術的階段。
-

Extender 紫杉醇藥物洗淨 PTCA 球囊導管
查看內容A 紫杉醇塗層 冠狀動脈球囊導管,旨在 減少再狭窄 在經皮冠狀血管成形術 (PTCA) 期間,可確保有效地將藥物輸送到血管壁。
-

Lotus Single Lumen & Double Lumen (RX) PTCA Microcatheter
查看內容Microcatheters 專為 冠脉 or peripheral lesion crossing, offering single- or double-lumen configurations for guidewire exchange, contrast injection, or subselective lesion access.
